Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Suffered 'Significant Loss Of Control' At McPherson Plant, US FDA Warning Letter Says

Executive Summary

Infractions that have delayed Copaxone generic in plant Pfizer acquired when it bought Hospira suggest that pattern of quality issues may be continuing. Warning letter assigns eight tasks related to particulate contamination.

Advertisement

Related Content

Keeping Track: Cardio, Antibiotic Approvals Put FDA Over Last Year's Novel Drug Count
Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes
Teva Catches A Break On Copaxone 40mg, But For How Long?
FDA Investigators Finding Fewer Deficiencies For Visual Inspection Programs
Pharma Pursues Generic Injectables Quality Turnaround Opportunities
FDA Calls for Greater Compliance With FAR Reporting Requirements

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120126

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel